Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 656-663

  Floris, Alberto ^a   Piga, Matteo ^a   Cauli, Alberto ^a   Mathieu, Alessandro ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; DNA;

ANTIBODY BLOOD LEVEL; CAUCASIAN; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; ETHNICITY; FOLLOW UP; HUMAN; IMMUNOASSAY; INCIDENCE; LUPUS ERYTHEMATOSUS NEPHRITIS; PATIENT CARE; PATIENT SELECTION; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; BLOOD; FEMALE; IMMUNOLOGY; MALE; PATHOLOGY; RECURRENT DISEASE; YOUNG ADULT;

ADULT; ANTIBODIES, ANTINUCLEAR; BIOMARKERS; DNA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RECURRENCE; YOUNG ADULT;

EID: 84959897497     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.02.019     Document Type: Review

References (44)

1. Cervera R., Abarca-Costalago M., Abramovicz D., et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev 2006, 5:180-186.
2. Barr S.G., Zonana-Nacach A., Magder L.S., et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999, 42:2682-2688.
3. Ruperto N., Hanrahan L.M., Alarcón G.S., et al. International consensus for a definition of disease flare in lupus. Lupus 2011, 20:453-462.
4. Ugarte-Gil M.F., Acevedo-Vásquez E., Alarcón G.S., et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015, 74:1019-1023.
5. Doria A., Rinaldi S., Ermani M., Salaffi F., Iaccarino L., Ghirardello A., et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004, 43:1580-1586.
6. Piga M., Casula L., Perra D., et al. Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus 2016, 25:28-37.
7. Lee J., Dhillon N., Pope J. All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford) 2013, 52:905-909.
8. Doria A., Iaccarino L., La Montagna G., et al. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. Clin Exp Rheumatol 2015, 33:375-384.
9. Doria A., Amoura Z., Cervera R., et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014, 73:154-160.
10. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
11. Petri M., Orbai A.M., Alarcón G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
12. Mosca M., Tani C., Aringer M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69:1269-1274.
13. Hahn B.H., McMahon M.A., Wilkinson A., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012, 64:797-808.
14. Ter Borg E.J., Horst G., Hummel E.J., et al. Measurement of increases in Anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in Systemic Lupus Erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643.
15. Swaak A.J., Groenwold J., Aarden L.A., et al. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis 1982, 41:388-395.
16. Swaak A.J., Groenwold J., Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986, 45:359-366.
17. Linnik M.D., Hu J.Z., Heilbrunn K.R., Strand V., et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:1129-1137.
18. Ho A., Magder L.S., Barr S.G., Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2342-2349.
19. Bootsma H., Spronk P., Derkesn R., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345:1595-1599.
20. Pan N., Amigues I., Lyman S., et al. A surge in anti-dsDNA titre predicts a sever lupus flare within six months. Lupus 2014, 23:293-298.
21. Tseng C.E., Buyon J.P., Kim M., et al. Effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:3623-3632.
22. Esdaile J.M., Abrahamowicz M., Joseph L., et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996, 39:370-378.
23. Steiman A.J., Gladman D.D., Ibañez D., et al. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010, 1822:7.
24. Isenberg D.A., Rahman A., Allen E., et al. BILAG 2004. Development and initial validation of an update version of the British Iseles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005, 44:902-906.
25. Petri M., Genovese M., Engle E., Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991, 34:937-944.
26. Zen M., Bassi N., Nalotto L., et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012, 30:856-863.
27. Van den Berg L., Nossent H., Rekvig O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol 2006, 25:347-352.
28. Petri M., Singh S., Tesfasyone H., et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009, 36:2476-2480.
29. Cervera R., Doria A., Amoura Z., et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 2014, 13:621-629.
30. Conti F., Ceccarelli F., Perricone C., et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 2012, 7.
31. Inês L., Duarte C., Silva R.S., Teixeira A.S., Fonseca F.P., da Silva J.A. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology 2014, 53:85-89.
32. Nikpour M., Urowitz M.B., Ibañez D., Gladman D.D. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009, 61:1152-1158.
33. Petri M.A., van Vollenhoven R.F., Buyon J., Levy R.A., Navarra S.V., Cervera R., et al. Freimuth WW; BLISS-52 and BLISS-76. Study groups. Baseline predictors of systemic lupus erythematosus flares data from the combined placebo groups in the phase III Belimumab trials. Arthritis Rheum 2013, 65:2143-2153.
34. Mirzayan M.J., Schmidt R.E., Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology 2000, 39:1316-1319.
35. Bertsias G.K., Tektonidou M., Amoura Z., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782.
36. Kavanaugh A.F., Solomon D.H. Guidelines for Immunologic Laboratory Testing in the Rheumatic disease: Anti-DNA Antibody Tests. Arthritis Rheum 2002, 47:546-555.
37. Bertsias G., Ioannidis J.P., Boletis J., et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008, 67:195-205.
38. Bijl M., Horst G., Bootsma H., Limburg P.C., Kallenberg C.G.M. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:534-539.
39. Agmon-Levin N., Damoiseaux G., Kallenberg C., et al. International recommendations for the assessment of autoantibodies to cellular antigens referred as anti-nuclear antibodies. Ann Rheum Dis 2014, 73:17-23.
40. Beça S., Rodríguez-Pintó I., Alba M.A., Cervera R., Espinosa G. Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. Autoimmun Rev 2015, 14:586-593.
41. Ruiz-Arruza I., Barbosa C., Ugarte A., Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 2015, 14:875-879.
42. Chatham W.W., Kimberly R.P. Treatment of lupus with corticosteroids. Lupus 2001, 10:140-147.
43. Petri M., Purvey S., Fang H., et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012, 64:4021-4028.
44. Piga M., Peltz M.T., Montaldo C., et al. Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev 2015, 14:510-516.